What is SLE Phase III Lupuzor?

Category: Others

false

The SLE Phase III Lupuzor trial is a randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with Systemic Lupus Erythematosus. NCT02504645

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
1

Commonly reported side effects and conditions associated with SLE Phase III Lupuzor

Side effect Patients

Dosages

Based on patients currently using SLE Phase III Lupuzor

Dosage Patients
200 mcg monthly 1

Why patients stopped taking SLE Phase III Lupuzor

Multiple reasons could be selected

Reason Patients
Did not seem to work 1
See 1 patient who's stopped using SLE Phase III Lupuzor

Duration

Currently using SLE Phase III Lupuzor

Duration Patients
1 - 2 years 1

Stopped using SLE Phase III Lupuzor

Duration Patients
6 months - 1 year 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for SLE Phase III Lupuzor.